Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 8/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20722735 | 1.00 | MAP4K4 (0.37) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL21684799 | 1.00 | MAP4K4 (0.37) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL20722733 | 1.00 | MAP4K4 (0.37) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL31204568 | 1.00 | MAP4K4 (0.37) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL20722392 | 0.90 | MAP4K4 (0.38) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL30968484 | 0.90 | MAP4K4 (0.38) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL30968531 | 0.90 | MAP4K4 (0.38) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL20722631 | 0.90 | MAP4K4 (0.38) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL30061949 | 0.90 | MAP4K4 (0.38) | MAP4K4PDE10ARETEIF2AK4BTK | |
| SCHEMBL28574715 | 0.90 | MAP4K4 (0.38) | MAP4K4PDE10ARETEIF2AK4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | MAP4K4 1430/4885PDE10A 4340/4885RET 2145/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | MAP4K4 1430/4885PDE10A 4340/4885RET 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.